We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$173M
AUM Growth
+$11M
Cap. Flow
+$39.8M
Cap. Flow %
23.02%
Top 10 Hldgs %
48.18%
Holding
76
New
24
Increased
16
Reduced
11
Closed
16

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$10.2M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$5.3M
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$4.37M
4
IMMU
Immunomedics Inc
IMMU
+$4.37M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$4.03M

Top Sells

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$8.74M
2
FOLD
Amicus Therapeutics
FOLD
+$5.81M
3
AVID
Avid Technology Inc
AVID
+$3.07M
4
LMAT icon
LeMaitre Vascular
LMAT
+$3.02M
5
TLGT
Teligent, Inc
TLGT
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 74.16%
2 Consumer Discretionary 2.56%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$19.7M 11.38%
1,404,667
-370,333
-21% -$5.81M
EXEL icon
2
Exelixis
EXEL
$13.8B
$10.5M 6.11%
+1,880,004
New +$10.2M
NDRM
3
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$10.3M 5.94%
496,630
+196,630
+66% +$4.03M
ASND icon
4
Ascendis Pharma A/S
ASND
$16B
$8.32M 4.81%
469,893
+48,042
+11% +$935K
IWM icon
5
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$7.64M 4.43%
70,000
– –
IOVA icon
6
Iovance Biotherapeutics
IOVA
$1.93B
$7.57M 4.38%
1,314,959
+428,959
+48% +$3.34M
BEAT
7
DELISTED
BioTelemetry, Inc.
BEAT
$5.51M 3.19%
450,000
-210,000
-32% -$2.68M
CYNA
8
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$5.07M 2.94%
313,524
+143,908
+85% +$2.34M
XBI icon
9
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$4.36M 2.52%
+70,000
New +$5.52M
LXRX icon
10
Lexicon Pharmaceuticals
LXRX
$1.03B
$4.3M 2.49%
+400,000
New +$4.37M
VCYT icon
11
Veracyte
VCYT
$3.58B
$4.24M 2.46%
905,000
+106,900
+13% +$1.02M
RRM
12
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
$3.85M 2.23%
469,350
+59,350
+14% +$432K
PTX
13
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$3.5M 2.03%
+110,872
New +$5.3M
INNL
14
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$3.43M 1.99%
273,981
+36,694
+15% +$506K
LJPC
15
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.4M 1.97%
+122,222
New +$3.85M
NBRV
16
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.34M 1.93%
+1,405
New +$3.72M
CASM
17
DELISTED
CAS Medical Systems, Inc.
CASM
$3.18M 1.84%
2,547,299
+191,944
+8% +$227K
WBMD
18
DELISTED
WebMD Health Corp.
WBMD
$3.17M 1.84%
+79,702
New +$3.37M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.24B
$3.09M 1.79%
+271,399
New +$3.62M
SPNC
20
DELISTED
Spectranetics Corp
SPNC
$3.06M 1.77%
260,000
+10,000
+4% +$179K
IRIX icon
21
IRIDEX
IRIX
$14.4M
$3.02M 1.75%
397,196
+84,746
+27% +$610K
IMMU
22
DELISTED
Immunomedics Inc
IMMU
$2.94M 1.7%
+1,711,067
New +$4.37M
AGTC
23
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.91M 1.68%
221,138
-526,862
-70% -$8.74M
BBW icon
24
Build-A-Bear
BBW
$424M
$2.89M 1.67%
152,876
-47,124
-24% -$892K
SGNT
25
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$2.8M 1.62%
182,618
+154,618
+552% +$3.34M
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2015 Portfolio in Review

As of Q3 2015, Acuta Capital Partners held 76 positions worth $173M, up 6.8% from $162M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Acuta Capital Partners deployed $39.8M of net new capital in Q3 2015, opening 24 new positions and adding to 16 existing holdings. Its largest new stake was Exelixis: 1,880,004 shares worth $10.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 81% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Applied Genetic Technologies Corporation, an estimated $8.74M trimmed.

  • Acuta Capital Partners's largest Q3 2015 buy was Exelixis: 1,880,004 shares worth $10.5M.
  • Acuta Capital Partners added most to NeuroDerm Ltd. Ordinary Shares in Q3 2015, an estimated $4.03M increase.
  • Acuta Capital Partners's biggest Q3 2015 reduction was Applied Genetic Technologies Corporation, cutting an estimated $8.74M.
  • Acuta Capital Partners fully exited Avid Technology Inc in Q3 2015, selling an estimated $3.07M.
  • Acuta Capital Partners's ten largest holdings make up 48% of its $173M portfolio in Q3 2015.
  • Acuta Capital Partners opened 24 new positions and closed 16 in Q3 2015.
  • Acuta Capital Partners's portfolio value rose 6.8% quarter-over-quarter to $173M.

Based on Acuta Capital Partners's 13F filing for Q3 2015, filed 16 Nov 2015.